THERAPEUTIC EFFECTIVENESS OF MINIMAL DOSES OF RITUXIMAB IN A PATIENT WITH RHEUMATOID ARTHRITIS

被引：11

作者：

Bruzzese, V. ^{[1
]}

机构：

[1] Nuovo Regina Margherita Hosp, CHU Internal Med, Sect Rheumatol, Rome, Italy

来源：

INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY | 2011年 / 24卷 / 01期

关键词：

rheumatoid arthritis; minimal dose of rituximab; CD20; depletion; effectiveness; EFFICACY; SAFETY; TRIAL;

D O I：

10.1177/039463201102400135

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We report the case of a man suffering from rheumatoid arthritis, resistant to common DMARDs and anti-TNF-alpha, who received an excellent response, in terms of effectiveness and depletion of CD20 positive B-lymphocytes, to minimal doses of anti-CD20 monoclonal antibody (rituximab). The dose used was only 100 mg, repeated after 2 weeks. Already after the first infusion of rituximab, a profound depletion of CD20 B-lymphocytes and an improvement of clinical symptoms were evident. The patient, after 4 months from the first two infusions, maintained an accentuated lymphocyte depletion and obtained a low disease activity, passing from an initial DAS28 of 6.3 to a DAS28 of 2.8. The possible practical implications of this observation are taken into consideration.

引用

页码：265 / 267

页数：3

共 5 条

[1] Unexpected and persistent depletion of B lymphocytes CD20 following a minimum dose of anti-CD20 antibody (Rituximab) [J].

Bruzzese, V. ;

Pepe, J. .

REUMATISMO, 2009, 61 (04) :306-308

[2] Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks [J].

Cohen, Stanley B. ;

Emery, Paul ;

Greenwald, Maria W. ;

Dougados, Maxime ;

Furie, Richard A. ;

Genovese, Mark C. ;

Keystone, Edward C. ;

Loveless, James E. ;

Burmester, Gerd-Ruediger ;

Cravets, Matthew W. ;

Hessey, Eva W. ;

Shaw, Timothy ;

Totoritis, Mark C. .

ARTHRITIS AND RHEUMATISM, 2006, 54 (09) :2793-2806

[3] Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)) [J].

Emery, P. ;

Deodhar, A. ;

Rigby, W. F. ;

Isaacs, J. D. ;

Combe, B. ;

Racewicz, A. J. ;

Latinis, K. ;

Abud-Mendoza, C. ;

Szczepanski, L. J. ;

Roschmann, R. A. ;

Chen, A. ;

Armstrong, G. K. ;

Douglass, W. ;

Tyrrell, H. .

ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (09) :1629-1635

[4] Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis [J].

Leandro, MJ ;

Cambridge, G ;

Ehrenstein, MR ;

Edwards, JCW .

ARTHRITIS AND RHEUMATISM, 2006, 54 (02) :613-620

[5] Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an Anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8) [J].

Winkler, U ;

Jensen, M ;

Manzke, O ;

Schulz, H ;

Diehl, V ;

Engert, A .

BLOOD, 1999, 94 (07) :2217-2224

← 1 →